Metabolic Disorders and Diagnostic Techniques in Hereditary Fructose Intolerance

Hereditary fructose intolerance (HFI) is an autosomal recessive inborn error of metabolism caused by deficiency of aldolase B, the hepatic enzyme responsible for the cleavage of fructose-1-phosphate. Accumulation of this intermediate leads to inhibition of key pathways such as gluconeogenesis and glycogenolysis, resulting in postprandial hypoglycaemia, vomiting, abdominal pain and aversion to sweet foods. Long-term manifestations include hepatic steatosis, growth failure, Fanconi-type renal tubular dysfunction and cardiovascular changes. Management centres on a life-long fructose-, sucrose- and sorbitol-restrictive diet to prevent metabolic intoxication and organ damage. Early detection is critical to avert acute crises and chronic complications, yet diagnosis can be challenging because symptoms overlap with other paediatric disorders. Diagnostic techniques span biochemical assays—measurement of carbohydrate-deficient transferrin (CDT) and other glycoforms—to genetic testing of the ALDOB gene, with emerging molecular and electrophoretic methods enhancing specificity. Practical tools such as digital health applications are being developed to support treatment adherence and drug tolerability. A multidisciplinary approach combining clinical assessment, dietary management, laboratory biomarkers and molecular confirmation underpins best practice in HFI care, with global implications for screening policies and patient education.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Metabolic Disorders and Diagnostic Techniques in Hereditary Fructose Intolerance publication trend

The graph below shows the total number of articles in metabolic disorders and diagnostic techniques in hereditary fructose intolerance across all publications each year (not limited to Nature Index journals).

Technical terms

Aldolase B: Hepatic enzyme that catalyses the cleavage of fructose-1-phosphate in fructose metabolism.

Fructose-1-phosphate: Glycolytic intermediate whose accumulation in hepatocytes disrupts energy pathways in HFI.

Carbohydrate-deficient transferrin (CDT): Abnormal serum transferrin glycoform used as a biomarker of fructose exposure and dietary adherence.

Capillary zone electrophoresis: High-resolution technique for separating serum proteins and detecting specific transferrin isoforms.

Fructose-, sucrose- and sorbitol-restrictive diet (FSS-free diet): Lifelong dietary regimen excluding fructose and related sugars to prevent HFI manifestations.

Excipient: Inactive substance in pharmaceutical formulations that may contain fructose or related compounds.

References

1. Design of mobile and website health application devices for drug tolerability in hereditary fructose intolerance. Orphanet Journal of Rare Diseases (2024).
2. Kidney and vascular function in adult patients with hereditary fructose intolerance. Molecular Genetics and Metabolism Reports (2020).
3. Clinical Practice Guidelines for the Diagnosis and Management of Hereditary Fructose Intolerance. Diseases (2024).
4. Transferrin Isoforms, Old but New Biomarkers in Hereditary Fructose Intolerance. Journal of Clinical Medicine (2021).